Clifutinib

Clifutinib (Compound 9e) is an orally active and selective internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) inhibitor with an IC50 value of 15.1 nM. Clifutinib inhibits the activity of FLT3-ITD kinase and blocks the downstream RAS/MAPK, PI3K/AKT, and JAK/STAT5 signaling pathways of FLT3. Clifutinib is promising for research of relapsed/refractory FLT3-ITD-positive acute myeloid leukemia.


Cat. No.: EX-A12416	Purity: >98%

	Chemical structure of Clifutinib

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
25mg	315	In-stock
50mg	500	In-stock
100mg	800	In-stock
250mg	1580	In-stock
500mg	2500	In-stock
1g	3980	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	1862226-99-0
Purity	>98%
Formula	C29H34N4O4
Mol Weight	502.6047
State	solid powder
Solubility	Soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder 4℃, sealed storage, 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Liu B, et al. Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia. J Med Chem. 2025 Apr 24;68(8):7955-7972.
CoA	CoA of Clifutinib

Smiles:	O=C(NC1=NOC(=C1)C(C)(C)C)NC2=CC=C(C#CC3=CC=C(OCCCN4CCOCC4)C=C3)C=C2


		Search